


Express Mail Label No.: EV074975407US
Date of Deposit: March 7, 2003

Attorney Docket No.: 23239-301A
(Formerly 23239-539)

#16/244



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Ellington, et al.

Examiner: Gibbs, Terra

APPLICATION NUMBER: 09/661,658

Art Unit: 1635

FILING DATE: September 14, 2000

FOR: ALLOSTERICALLY REGULATED RIBOZYMES

RECEIVED
MAR 12 2003
TECH CENTER 1600/2900

Box IDS

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references. Previous counsel cited thirty United States Patent Documents, four Foreign Patent Documents and three other pieces of journal art without labeling the art alpha-numerically. Present counsel takes the previous citations into account and presents this Supplemental Information Disclosure beginning with the thirty-first United States Patent Document, fifth Foreign Patent Document and the fourth piece of journal art labeled alpha-numerically.

Note that B7 and B10 are foreign language documents. English language abstracts have been provided for these references as documents B11 and B12.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the International Search Report for PCT/ US 01/19302 that corresponds to the above-identified application. Accordingly, no fee or certification is believed required.

A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that


Applicants: Ellington, et al.
U.S.S.N.: 09/661,658

the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 23239-301A.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: March 7, 2003

TRA 1771067v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAR 12 2003
TECH CENTER 1600/2900

APPLICANT: Ellington, et al.
APPLICATION NUMBER: 09/661,658
FILING DATE: September 14, 2000
FOR: ALLOSTERICALLY REGULATED RIBOZYMES
Examiner: Gibbs, Terra
Art Unit: 1635

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of cited references A31, B5-B12, and C4-C10; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23239-301A. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



30623

PATENT TRADEMARK OFFICE

Ivor R. Elrifi
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.


One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: March 7, 2003

Express Mail No.: EV074975407US
Date of Deposit: March 7, 2003

Please type a plus sign (+) in this box

+



Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	09/661,658
Filing Date	September 14, 2000
First Named Inventor	Ellington
Group Art Unit	1635
Examiner Name	Gibbs, Terra C
Attorney Docket Number	23239-301A (Formerly 23239-539)

Page 1 of 1
RECEIVED
MAR 12 2003
TECH CENTER 1500/2900

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A31	5,443,791	08/22/95	Cathcart, et al.			08/07/92

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B5	WO 96/06944	The General Hospital Corporation	03/07/96		
	B6	WO 98/27104	Yale University	06/25/98		
	B7	WO 99/16781	Roche Diagnostics GMBH	04/08/99		X
	B8	WO 99/57561	Ammann, Kelly	11/11/99		
	B9	WO 00/43534	Somalogic, Inc.	07/27/00		
	B10	FR 2 633 310	Institut Pasteur	12/29/89		X
	B11	FR 2 633 310	Institut Pasteur (English Language Abstract Only)	12/29/89		
	B12	WO 99/16781	Roche Diagnostics GMBH (English Language Abstract Only)	04/08/99		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C4	Cox, et al. (1998). Biotechnol Prog 14: 845-850.
	C5	Ellington, Andrew (1994). Curr Biol 4(5): 427-429.
	C6	International Search Report for PCT US 01/19302, mailed January 22, 2003.
	C7	Koizumi, et al. (1999). Nat Struct Biol 6(11): 1062-1071.
	C8	Marshall and Ellington (1999). Nat Struct Biol 6(11): 992-994.
	C9	Robertson and Ellington (2000). Nucl Acid Res 28(8): 1751-1759.
	C10	Xu, et al. (1996). Proc Natl Acad Sci USA 93(15): 7475-7480.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. § 120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.